MONTREAL, QUEBEC, Jul 07, 2008 (MARKET WIRE via COMTEX) ----Thallion Pharmaceuticals Inc. (TSX: TLN) will release its second quarter results for 2008 on Thursday, July 10, 2008 at 4:30 PM Eastern Time. The Company will subsequently hold a conference call on Monday, July 14, 2008 at 4:30 PM Eastern Time hosted by Mr. Lloyd M. Segal, Chief Executive Officer and Mr. Michael Singer, Chief Financial Officer. A question and answer session will follow the corporate update.

CONFERENCE CALL DETAILS

 DATE: July 14, 2008 TIME: 4:30 PM Eastern Time
   DIAL IN NUMBER: 416-644-3414 or 800-733-7571 TAPED REPLAY: 416-640-1917 or 877-289-8525 REFERENCE NUMBER: 21276824# 

A live audio webcast of the conference call will be available by visiting the Company's website at www.thallion.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of oncology and infectious disease. Thallion has three clinical programs at a Phase II, or later, stage of development. Two late stage Phase II oncology trials which include: TLN-4601, a novel anti-cancer therapy derived from a nonpathogenic microorganism and TLN-232, a targeted therapy with potential efficacy in multiple oncology indications. The Company's third product candidate, Shigamabs(R), is a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections. Additional information about the Company can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

 Contacts: Thallion Pharmaceuticals
   Inc. Michael Singer Chief Financial Officer 514-940-3600 514-228-3622 (FAX) info@thallion.com www.thallion.com The Equicom
   Group Inc. Ross Marshall Investor Relations 416-815-0700 (Ext. 238) 416-815-0080 (FAX) rmarshall@equicomgroup.com 

SOURCE: Thallion Pharmaceuticals Inc.

mailto:info@thallion.com http://www.thallion.com mailto:rmarshall@equicomgroup.com
   

Copyright 2008 Market Wire, All rights reserved.